Advertisement

Five-Year Incidence and Visual Outcomes in Postintravitreal Injection Endophthalmitis

Published:December 30, 2015DOI:https://doi.org/10.1016/j.ophtha.2015.11.019
      Although intravitreal injections are considered a great advancement in the management of retinal diseases because they have potential to improve vision, endophthalmitis is a concern to a treating ophthalmologist.
      • Dossarps D.
      • Bron A.M.
      • Koehrer P.
      • et al.
      FRCR net (FRenCh Retina specialists net). Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome.
      • Mithal K.
      • Mathai A.
      • Pathengay A.
      • et al.
      Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome.
      Previous studies have found a prevalence of postinjection endophthalmitis of 0% to 0.87%. The purpose of this study is to report the incidence, microbiological profile, antimicrobial susceptibility, clinical findings, management, and visual outcomes in patients with acute postinjection endophthalmitis (within 6 weeks) after anti-vascular endothelial growth factor and intravitreal injection of triamcinolone acetonide (IVTA).
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dossarps D.
        • Bron A.M.
        • Koehrer P.
        • et al.
        FRCR net (FRenCh Retina specialists net). Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome.
        Am J Ophthalmol. 2015; 160: 17-25
        • Mithal K.
        • Mathai A.
        • Pathengay A.
        • et al.
        Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome.
        Br J Ophthalmol. 2013; 97: 1609-1612
        • Moshfeghi A.A.
        • Rosenfeld P.J.
        • Flynn Jr., H.W.
        • et al.
        Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center.
        Retina. 2011; 31: 662-668
        • Nentwich M.M.
        • Yactayo-Miranda Y.
        • Schwarzbach F.
        • et al.
        Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center.
        Retina. 2014; 34: 943-950
        • Casparis H.
        • Wolfensberger T.J.
        • Becker M.
        • et al.
        Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
        Retina. 2014; 34: 12-17

      Linked Article